Feature

Keep an eye on the HPV p16 protein in head and neck cancer


 

At the 2014 Multidisciplinary Head and Neck Cancer Symposium in Scottsdale, Arizona, experts presented their findings on novel therapies and surgical and radiotherapeutic techniques with a view to improving outcomes, refining supportive care, and easing toxicity. Neil Osterweil reported from the symposium, which was sponsored by the American Society for Radiation Oncology, the American Society of Clinical Oncology, and the American Head & Neck Society...

Click on the PDF icon at the top of this introduction to read the full article.

Recommended Reading

Thyroid cancer rise mostly overdiagnosis
MDedge Hematology and Oncology
Gland-sparing technique safe in tonsillar, tongue cancers
MDedge Hematology and Oncology
Humidification mitigates radiation-induced mucositis, but compliance is a problem
MDedge Hematology and Oncology
Overall survival from recurrent head and neck cancer double among HPV+ patients
MDedge Hematology and Oncology
The push for smaller, smarter cancer trials
MDedge Hematology and Oncology
Experimental EGFR inhibitor added nothing but rash
MDedge Hematology and Oncology
Chemoradiation offered better survival than accelerated radiation in head and neck squamous cell carcinomas
MDedge Hematology and Oncology
Younger men with goiter at higher risk for thyroid cancers
MDedge Hematology and Oncology
High-volume surgeons have best adrenalectomy outcomes
MDedge Hematology and Oncology
Thyroglobulin washout boosts diagnostic sensitivity in recurrent thyroid cancer
MDedge Hematology and Oncology